Comparison of the effects of human β-defensin 3, vancomycin, and clindamycin on Staphylococcus aureus biofilm formation

Orthopedics

Volumn 35, Issue 1, 2012, Pages

  Huang, Qiang ^a   Yu, Hong Jun ^b   Liu, Guo Dong ^a   Huang, Xian Kai ^a   Zhang, Lian Yang ^a   Zhou, Yong Gang ^c   Chen, Ji Ying ^c   Lin, Feng ^c   Wang, Yan ^c   Fei, Jun ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 3; CLINDAMYCIN; VANCOMYCIN;

ARTICLE; BACTERIAL SURVIVAL; BACTERIAL VIABILITY; BIOFILM; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BETA-DEFENSINS; BIOFILMS; CELL SURVIVAL; CLINDAMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 84862959199     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20111122-11     Document Type: Article

References (29)

1. Siegenthaler MP, Martin J, Beyersdorf F. Mechanical circulatory assistance for acute and chronic heart failure: a review of current technology and clinical practice. J Interv Cardiol. 2003; 16(6):563-572. (Pubitemid 37431025)
2. Hebert CK, Williams RE, Levy RS, Barrack RL. Cost of treating an infected total knee replacement. Clin Orthop Relat Res. 1996; (331):140-145. (Pubitemid 26357698)
3. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med. 2004; 350(14):1422-1429. (Pubitemid 38419996)
4. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999; 284(5418):1318-1322. (Pubitemid 29289651)
5. Donlan RM. Biofilm formation: a clinically relevant microbiological process [published online ahead of print September 20, 2011]. Clin Infect Dis. 2001; 33(8):1387-1392. (Pubitemid 32955193)
6. Curtin JJ, Donlan RM. Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother. 2006; 50(4):1268-1275.
7. Donlan RM. Preventing biofilms of clinically relevant organisms using bacteriophage [published online ahead of print January 21, 2009]. Trends Microbiol. 2009; 17(2):66-72.
8. Doolittle MM, Cooney JJ, Caldwell DE. Tracing the interaction of bacteriophage with bacterial biofilms using fluorescent and chromogenic probes. J Ind Microbiol. 1996; 16(6):331-341.
9. Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system [published online ahead of print October 12, 2009]. Antimicrob Agents Chemother. 2010; 54(1):397-404.
10. van der Plas MJ, Jukema GN, Wai SW, et al. Maggot excretions/secretions are differentially effective against biofilms of Staphylococcus aureus and Pseudomonas aeruginosa [published online ahead of print October 26, 2007]. J Antimicrob Chemother. 2008; 61(1):117-122.
11. van der Plas MJ, Dambrot C, Dogterom- Ballering HC, Kruithof S, van Dissel JT, Nibbering PH. Combinations of maggot excretions/secretions and antibiotics are effective against Staphylococcus aureus biofilms and the bacteria derived therefrom [published online ahead of print February 26, 2010]. J Antimicrob Chemother. 2010; 65(5):917-923.
12. Stallmann HP, Faber C, Nieuw Amerongen AV, Wuisman PI. Antimicrobial peptides: review of their application in musculoskeletal infections. Injury. 2006; 37(suppl 2):S34-S40.
13. Warnke PH, Springer IN, Russo PA, et al. Innate immunity in human bone [published online ahead of print November 2, 2005]. Bone. 2006; 38(3):400-408. (Pubitemid 43255435)
14. Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic [published online ahead of print November 20, 2000]. J Biol Chem. 2001; 276(8):5707-5713.
15. Joly S, Maze C, McCray PB Jr, Guthmiller JM. Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J Clin Microbiol. 2004; 42(3):1024-1029. (Pubitemid 38332820)
16. Maisetta G, Batoni G, Esin S, et al. In vitro bactericidal activity of human beta-defensin 3 against multidrug-resistant nosocomial strains. Antimicrob Agents Chemother. 2006; 50(2):806-809. (Pubitemid 43191008)
17. Sahly H, Schubert S, Harder J, Rautenberg P, Ullmann U, Schröder J, Podschun R. Burkholderia is highly resistant to human Beta-defensin 3. Antimicrob Agents Chemother. 2003; 47(5):1739-1741. (Pubitemid 36548564)
18. Maisetta G, Batoni G, Esin S, et al. Activity of human beta-defensin 3 alone or combined with other antimicrobial agents against oral bacteria. Antimicrob Agents Chemother. 2003; 47(10):3349-3351. (Pubitemid 37229604)
19. Li M, Cha DJ, Lai Y, Villaruz AE, Sturdevant DE, Otto M. The antimicrobial peptide-sensing system aps of Staphylococcus aureus [published online ahead of print October 24, 2007]. Mol Microbiol. 2007; 66(5):1136-1147. (Pubitemid 350115022)
20. Neut D, Hendriks JG, van Horn JR, van der Mei HC, Busscher HJ. Pseudomonas aeruginosa biofilm formation and slime excretion on antibiotic-loaded bone cement. Acta Orthop. 2005; 76(1):109-114.
21. Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J. Human beta-defensins. Cell Mol Life Sci. 2006; 63(11):1294-1313.
22. Hajdu S, Lassnigg A, Graninger W, Hirschl AM, Presterl E. Effects of vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms. J Orthop Res. 2009; 27(10):1361-1365.
23. Leung KP, Crowe TD, Abercrombie JJ, et al. Control of oral biofilm formation by an antimicrobial decapeptide. J Dent Res. 2005; 84(12):1172-1177. (Pubitemid 43827787)
24. Balaban N, Gov Y, Giacometti A, et al. A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci. Antimicrob Agents Chemother. 2004; 48(7):2544-2550. (Pubitemid 38823423)
25. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005; 3(3):238-250. (Pubitemid 40298223)
26. Vranes J. Effect of subminimal inhibitory concentrations of azithromycin on adherence of Pseudomonas aeruginosa to polystyrene. J Chemother. 2000; 12(4):280-285. (Pubitemid 30640380)
27. Harraghy N, Seiler S, Jacobs K, Hannig M, Menger MD, Herrmann M. Advances in in vitro and in vivo models for studying the staphylococcal factors involved in implant infections. Int J Artif Organs. 2006; 29(4):368-378.
28. Fei J, Yu HJ, Pan CJ, Zhao CH, Zhou YG, Wang Y. Efficacy of a norvancomycin-loaded, PDLLA-coated plate in preventing early infection of rabbit tibia fracture. Orthopedics. 2010; 33(5). doi: 10.3928/01477447-20100329-06
29. Fei J, Liu GD, Pan CJ, et al. Preparation, release profiles and antibacterial properties of vancomycin-loaded Ca-P coating titanium alloy plate [published online ahead of print March 19, 2011]. J Mater Sci Mater Med. 2011; 22(4):989-995.